

Steps taken following Prequalification of Lamivudine/Zidovudine 150 mg/300 mg Tablets*:

No variations with impact on the WHOPAR accepted by PQP at this moment.

* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's (NMRA) responsibility. Throughout this WHOPAR the Proprietary Name is given as an example only.